Candelaria

Researchers are evaluating the accuracy of a new three-dimensional imaging technology called the 3D-PANC MSP model compared to conventional computed tomography (CT) scans in patients with borderline or locally advanced pancreatic adenocarcinoma who have undergone neoadjuvant chemotherapy. The goal is to better identify patients who may benefit from surgical removal of the tumor by comparing both imaging methods to surgical and histopathological findings. This prospective multicenter study includes patients undergoing surgery with curative intent after chemotherapy over a one-year period. Participants will have preoperative images taken using both traditional CT and the 3D-MSP technology. The 3D model will be created centrally by a specialized team blinded to CT reports, while conventional CT scans will be performed at diagnosis and after chemotherapy, analyzed by radiologists blinded to surgical outcomes. Each patient will serve as their own control, with imaging results evaluated using NCCN guidelines checklists based on both methods. During the study, researchers will compare sensitivity, specificity, predictive values, and other accuracy measures of the two imaging techniques over an average of two months. The study involves detailed imaging analysis, surgical exploration, and histopathological assessment to determine vascular involvement before surgery. This approach aims to improve the preoperative evaluation of pancreatic cancer patients to guide treatment decisions more effectively.